Bovine Papillomavirus Type 1 Infection Is Mediated by SNARE Syntaxin 18

ABSTRACT Events that lead to viral infections include the binding of the virus to the target cells, internalization of the virus into the cells, and the ability of the viral genome to be expressed. These steps are mediated by cellular and viral proteins and are temporally regulated. The papillomavirus capsid consists of two virally encoded capsid proteins, L1 and L2. Much is known about the role of the major capsid protein L1 compared to what is known of the role of the L2 protein. We identified the interaction of the L2 protein with SNARE protein syntaxin 18, which mediates the trafficking of vesicles and their cargo between the endoplasmic reticulum, the cis-Golgi compartment, and possibly the plasma membrane. Mutations of L2 residues 41 to 44 prevented the interaction of L2 protein with syntaxin 18 in cotransfection experiments and resulted in noninfectious pseudovirions. In this paper, we describe that syntaxin 18 colocalizes with infectious bovine papillomavirus type 1 (BPV1) pseudovirions during infection but does not colocalize with the noninfectious BPV1 pseudovirions made with an L2 mutant at residues 41 to 44. We show that an antibody against BPV1 L2 residues 36 to 49 (αL2 36-49) binds to in vitro-generated BPV1 pseudoviral capsids and does not coimmunoprecipitate syntaxin 18- and BPV1 L2-transfected proteins. αL2 36-49 was able to partially or completely neutralize infection of BPV1 pseudovirions and genuine virions. These results support the dependence of syntaxin 18 during BPV1 infection and the ability to interfere with infection by targeting the L2-syntaxin 18 interaction and further define the infectious route of BPV1 mediated by the L2 protein.

[1]  R. Roden,et al.  A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. , 2007, Vaccine.

[2]  Y. Ishii,et al.  Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. , 2007, Virology.

[3]  I. Wada,et al.  Involvement of syntaxin 18, an endoplasmic reticulum (ER)-localized SNARE protein, in ER-mediated phagocytosis. , 2006, Molecular biology of the cell.

[4]  N. Christensen,et al.  Papillomavirus Particles Assembled in 293TT Cells Are Infectious In Vivo , 2006, Journal of Virology.

[5]  J. Bordeaux,et al.  The L2 Minor Capsid Protein of Low-Risk Human Papillomavirus Type 11 Interacts with Host Nuclear Import Receptors and Viral DNA , 2006, Journal of Virology.

[6]  Luise Florin,et al.  Identification of a Dynein Interacting Domain in the Papillomavirus Minor Capsid Protein L2 , 2006, Journal of Virology.

[7]  A. Hildesheim,et al.  Role of DC‐SIGN in the activation of dendritic cells by HPV‐16 L1 virus‐like particle vaccine , 2006, European journal of immunology.

[8]  D. Lowy,et al.  Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Lowy,et al.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. , 2005, Virology.

[10]  P. Ahlquist,et al.  Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  I. Bossis,et al.  Interaction of tSNARE Syntaxin 18 with the Papillomavirus Minor Capsid Protein Mediates Infection , 2005, Journal of Virology.

[12]  M. Ozbun,et al.  The Minor Capsid Protein L2 Contributes to Two Steps in the Human Papillomavirus Type 31 Life Cycle , 2005, Journal of Virology.

[13]  D. Lowy,et al.  Maturation of Papillomavirus Capsids , 2005, Journal of Virology.

[14]  D. Lowy,et al.  Generation of HPV pseudovirions using transfection and their use in neutralization assays. , 2005, Methods in molecular medicine.

[15]  R. Roden,et al.  The Positively Charged Termini of L2 Minor Capsid Protein Required for Bovine Papillomavirus Infection Function Separately in Nuclear Import and DNA Binding , 2004, Journal of Virology.

[16]  J. Moroianu,et al.  The L2 Minor Capsid Protein of Human Papillomavirus Type 16 Interacts with a Network of Nuclear Import Receptors , 2004, Journal of Virology.

[17]  D. Lowy,et al.  Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  U. Greber,et al.  Adenovirus endocytosis , 2004, The journal of gene medicine.

[19]  D. Lowy,et al.  Efficient Intracellular Assembly of Papillomaviral Vectors , 2004, Journal of Virology.

[20]  H. Selinka,et al.  Further Evidence that Papillomavirus Capsids Exist inTwo DistinctConformations , 2003, Journal of Virology.

[21]  N. Grassly,et al.  Back to basics in HIV prevention: focus on exposure , 2003, BMJ : British Medical Journal.

[22]  R. Roden,et al.  Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection , 2003, Journal of Virology.

[23]  P. Coursaget,et al.  Human Papillomavirus Types 16, 31, and 58 Use Different Endocytosis Pathways To Enter Cells , 2003, Journal of Virology.

[24]  D. Lowy,et al.  Papillomaviruses infect cells via a clathrin-dependent pathway. , 2003, Virology.

[25]  Neff Walker,et al.  HIV Surveillance: A Global Perspective , 2003, Journal of acquired immune deficiency syndromes.

[26]  M. Campo,et al.  Animal models of papillomavirus pathogenesis. , 2002, Virus research.

[27]  H. Selinka,et al.  Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. , 2002, Virology.

[28]  H. Selinka,et al.  DNA-Induced Structural Changes in the Papillomavirus Capsid , 2001, Journal of Virology.

[29]  D. Lowy,et al.  L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation , 2001, Journal of Virology.

[30]  P. Ghys,et al.  HIV surveillance among female sex workers. , 2001, AIDS.

[31]  D. Lowy,et al.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. , 2000, Virology.

[32]  R. Scheller,et al.  Syntaxin 18, a SNAP Receptor That Functions in the Endoplasmic Reticulum, Intermediate Compartment, and cis-Golgi Vesicle Trafficking* , 2000, The Journal of Biological Chemistry.

[33]  Y. Taketani,et al.  Common Neutralization Epitope in Minor Capsid Protein L2 of Human Papillomavirus Types 16 and 6 , 1999, Journal of Virology.

[34]  D. Lowy,et al.  The Papillomavirus Minor Capsid Protein, L2, Induces Localization of the Major Capsid Protein, L1, and the Viral Transcription/Replication Protein, E2, to PML Oncogenic Domains , 1998, Journal of Virology.

[35]  J. Ferlay,et al.  Cancer and infection: estimates of the attributable fraction in 1990. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  Benes L. Trus,et al.  Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 Å resolution , 1997, Nature Structural Biology.

[37]  M. Sapp,et al.  Generation and neutralization of pseudovirions of human papillomavirus type 33 , 1997, Journal of virology.

[38]  W. Liu,et al.  Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. , 1997, Virology.

[39]  G. Grindlay,et al.  Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. , 1996, The Journal of general virology.

[40]  J. Rohrer,et al.  The targeting of Lamp1 to lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to the membrane , 1996, The Journal of cell biology.

[41]  P. L. Campbell,et al.  EEA1, an Early Endosome-Associated Protein. , 1995, The Journal of Biological Chemistry.

[42]  P. Schirmacher,et al.  Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells , 1995, Journal of virology.

[43]  Darren W. Henderson,et al.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins , 1994, Journal of virology.

[44]  I. Frazer,et al.  Synthesis and assembly of infectious bovine papillomavirus particles in vitro. , 1993, The Journal of general virology.

[45]  N. Christensen,et al.  Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. , 1991, Virus research.

[46]  G. Orth,et al.  Genetic heterogeneity among human papillomaviruses (HPV) associated with epidermodysplasia verruciformis: evidence for multiple allelic forms of HPV5 and HPV8 E6 genes. , 1991, Virology.

[47]  C. Crum,et al.  Topography of early HPV 16 transcription in high-grade genital precancers. , 1989, The American journal of pathology.

[48]  J. Doorbar,et al.  Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a , 1987, Journal of virology.

[49]  D. DiMaio.  Nonsense mutation in open reading frame E2 of bovine papillomavirus DNA , 1986, Journal of virology.

[50]  I. Pastan,et al.  Transit of receptors for epidermal growth factor and transferrin through clathrin-coated pits. Analysis of the kinetics of receptor entry. , 1985, The Journal of biological chemistry.

[51]  P. Howley,et al.  Localization and analysis of bovine papillomavirus type 1 transforming functions , 1984, Journal of virology.

[52]  H. Hausen,et al.  Human papilloma viruses (HPV): characterization of four different isolates. , 1977, Virology.